Musculoskeletal PRP Applications with Alocuro PRO-PRP

Harnessing the Regenerative Potential of PRP in MSK Medicine

Platelet-Rich Plasma (PRP) is a highly clinically valuable regenerative therapy in orthopaedic and sports medicine, supporting tissue healing in tendons, ligaments, cartilage, and muscle. By delivering a concentrated dose of autologous growth factors and bioactive proteins directly to the site of injury, PRP offers a minimally invasive alternative to surgery or corticosteroids for a wide range of musculoskeletal conditions.

Alocuro’s PRO-PRP system delivers consistently high platelet concentrations with the option for leukocyte control, enabling clinicians to tailor the PRP formulation to the specific needs of the tissue being treated.

Mechanism of Action: How PRP Supports Tissue Healing

Upon activation, platelets release a complex mixture of growth factors, cytokines, and signalling molecules from their α-granules. These factors play a key role in:

  • Modulating the inflammatory response

  • Recruiting reparative cells

  • Stimulating angiogenesis

  • Promoting collagen synthesis and extracellular matrix remodelling

The regenerative cascade triggered by PRP follows three key phases:

  1. Inflammation (Day 1–3): Platelets initiate repair by releasing chemotactic factors and inflammatory mediators that recruit neutrophils and macrophages.

  2. Proliferation (Week 1–4): Fibroblasts, endothelial cells, and tenocytes proliferate; angiogenesis and new matrix formation occur.

  3. Remodelling (Weeks to Months): Type III collagen is replaced by Type I collagen; tissue tensile strength is restored.

This process is particularly useful in avascular tissues (e.g. tendons, cartilage), where natural healing is limited.

Clinical Indications for MSK PRP

PRP can be effectively used as a first-line regenerative option or as an adjunct to surgery in the following conditions:

Tendinopathies

  • Lateral epicondylitis (tennis elbow)

  • Patellar tendinopathy

  • Achilles tendinopathy

  • Rotator cuff tendinopathy

PRP has shown to outperform corticosteroid injections in long-term pain and function outcomes in many tendinopathies.

Ligament Injuries

  • Partial MCL or LCL tears

  • Mild to moderate ankle sprains

PRP may accelerate healing and reduce downtime, particularly in athletic populations.

Osteoarthritis (Intra-Articular Use)

  • Knee OA (Kellgren-Lawrence grades I–III)

  • Hip OA (early stage)

  • Glenohumeral and acromioclavicular joint OA

PRP has demonstrated pain and function improvement beyond hyaluronic acid or placebo in multiple RCTs, particularly at 6–12 months follow-up.

Muscle Injuries

  • Grade II hamstring, adductor, or quadriceps strains

  • Recurrent muscle tears

PRP may reduce re-injury risk and time to return to play when used alongside rehabilitation.

Post-Surgical Applications

  • Meniscal repair

  • ACL reconstruction

  • Tendon repairs

Used intra-operatively to enhance healing response and reduce scar tissue formation.

Why Alocuro PRP? Precision for Musculoskeletal Practice

Alocuro’s PRO-PRP system is engineered to meet the specific demands of musculoskeletal and orthopaedic applications:

  • Platelet concentration up to 9–12× baseline, optimised for dense connective tissue and cartilage environments.

  • 90–95% platelet recovery efficiency, delivering consistent, evidence-aligned doses.

  • Customisable leukocyte profile, allowing production of leukocyte-rich PRP for tendon or ligament injuries, and leukocyte-poor PRP for intra-articular or cartilage applications.

  • No thixotropic gel or artificial separator, preserving platelet viability and avoiding unwanted chemical residues.

  • TGA-registered, sterile, closed-system design for procedural safety and compliance.

Ideal Patient Profile

PRP is most effective when applied to:

  • Localised pathology confirmed by clinical and/or imaging findings

  • Mild to moderate degenerative changes (OA)

  • Partial tears and non-retracted injuries

  • Cases that have failed first-line conservative treatment (physio, NSAIDs)

Not suitable for systemic inflammatory arthritis, active infection, or malignancy.

Treatment Protocol & Expectations

  • Injection typically performed under ultrasound guidance for accuracy.

  • Post-injection response: Mild inflammatory flare (24–48 hours), followed by gradual symptom improvement.

  • Patients may require 1–3 treatments, spaced 2–4 weeks apart.

  • Best outcomes when combined with graded rehabilitation, biomechanical correction, and load management.

  • NSAIDs should be avoided for 5–7 days pre- and post-procedure unless clinically necessary.

Evidence-Based Outcomes

In randomised trials, PRP has demonstrated:

  • Superior long-term outcomes to corticosteroids for tennis elbow and patellar tendinopathy.

  • Delayed OA progression and reduced pain scores in early knee osteoarthritis.

  • Improved tendon structural healing on ultrasound or MRI post-treatment.

The International Olympic Committee supports the use of leukocyte-optimised PRP in athletes, noting a favourable safety profile and growing evidence base for MSK use.

Interested in the Research?

Alocuro maintains a curated library of peer-reviewed articles and clinical studies supporting the use of PRP in musculoskeletal medicine. If you would like access to our collection of scientific literature, including independent trials and outcome data aligned with our system, please contact our team directly.

Reach out via info@alocuro.com.au to request access to our collated research summaries and literature library.

Get in touch to explore how Alocuro can elevate your practice

Contact Us